Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acteoside (also known as verbascoside) is a phenylethanoid glycoside widely distributed in the plant kingdom, notably in species such as *Verbascum sinuatum* and *Cistanche tubulosa*. It is characterized by its potent antioxidant, anti-inflammatory, and neuroprotective properties. Mechanistically, acteoside acts by scavenging free radicals, inhibiting the activation of the NF-κB signaling pathway, and inducing the Nrf2-mediated antioxidant response. It has also been shown to inhibit protein kinase C (PKC) and 5-lipoxygenase. Due to its ability to cross the blood-brain barrier and reduce amyloid-beta aggregation and tau hyperphosphorylation in preclinical models, it is a subject of significant interest for the treatment of neurodegenerative disorders like Alzheimer's and Parkinson's diseases. Additionally, it exhibits hepatoprotective and anti-tumor activities in various experimental settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acteoside.